Myxobacteria: Natural pharmaceutical factories

Microbial Cell Factories

Volumn 11, Issue , 2012, Pages

  Diez, Juana ^a   Martinez, Javier P ^a   Mestres, Jordi ^a   Sasse, Florenz ^b   Frank, Ronald ^b   Meyerhans, Andreas ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Chemical space; Drug discovery; Myxobacteria; Natural products

Indexed keywords

DRUG METABOLITE; NATURAL PRODUCT; PEPTIDE; POLYKETIDE; BIOLOGICAL PRODUCT;

ANTIVIRAL ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MEDICINAL SPECIES; MYXOCOCCALES; MYXOCOCCUS XANTHUS; NONHUMAN; NOTE; SORANGIUM CELLULOSUM; BACTERIAL SPORE; DRUG DEVELOPMENT; EDITORIAL; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM;

FUNGI; MYXOCOCCALES;

BIOLOGICAL AGENTS; DRUG DISCOVERY; MYXOCOCCALES; SPORES, BACTERIAL;

EID: 84862229590     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/1475-2859-11-52     Document Type: Note

References (35)

1. Davies J, Ryan KS. Introducing the parvome: bioactive compounds in the microbial world. ACS Chem Biol 2012, 7(2):252-259. 10.1021/cb200337h, 22074935.
2. Mishra BB, Tiwari VK. Natural products: an evolving role in future drug discovery. Eur J Med Chem 2011, 46(10):4769-4807. 10.1016/j.ejmech.2011.07.057, 21889825.
3. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012, 75(3):311-335. 10.1021/np200906s, 22316239.
4. Arguelles-Arias A, Ongena M, Halimi B, Lara Y, Brans A, Joris B, Fickers P. Bacillus amyloliquefaciens GA1 as a source of potent antibiotics and other secondary metabolites for biocontrol of plant pathogens. Microb Cell Fact 2009, 8:63. 10.1186/1475-2859-8-63, 2787494, 19941639.
5. Bode HB, Muller R. Analysis of myxobacterial secondary metabolism goes molecular. J Ind Microbiol Biotechnol 2006, 33(7):577-588. 10.1007/s10295-006-0082-7, 16491362.
6. Weissman KJ, Muller R. Myxobacterial secondary metabolites: bioactivities and modes-of-action. Nat Prod Rep 2010, 27(9):1276-1295. 10.1039/c001260m, 20520915.
7. Gentzsch J, Hinkelmann B, Kaderali L, Irschik H, Jansen R, Sasse F, Frank R, Pietschmann T. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Antiviral Res 2011, 89(2):136-148. 10.1016/j.antiviral.2010.12.005, 21167208.
8. Nickeleit I, Zender S, Sasse F, Geffers R, Brandes G, Sorensen I, Steinmetz H, Kubicka S, Carlomagno T, Menche D, et al. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008, 14(1):23-35. 10.1016/j.ccr.2008.05.016, 18598941.
9. Reichenbach H. Myxobacteria, producers of novel bioactive substances. J Ind Microbiol Biotechnol 2001, 27(3):149-156. 10.1038/sj.jim.7000025, 11780785.
10. Velicer GJ, Vos M. Sociobiology of the myxobacteria. Annu Rev Microbiol 2009, 63:599-623. 10.1146/annurev.micro.091208.073158, 19575567.
11. Kaiser D. Coupling cell movement to multicellular development in myxobacteria. Nat Rev 2003, 1(1):45-54.
12. Nan B, Chen J, Neu JC, Berry RM, Oster G, Zusman DR. Myxobacteria gliding motility requires cytoskeleton rotation powered by proton motive force. Proc Natl Acad Sci USA 2011, 108(6):2498-2503. 10.1073/pnas.1018556108, 3038734, 21248229.
13. Xiao Y, Wei X, Ebright R, Wall D. Antibiotic production by myxobacteria plays a role in predation. J Bacteriol 2011, 193(18):4626-4633. 10.1128/JB.05052-11, 3165673, 21764930.
14. Berleman JE, Kirby JR. Deciphering the hunting strategy of a bacterial wolfpack. FEMS Microbiol Rev 2009, 33(5):942-957. 10.1111/j.1574-6976.2009.00185.x, 2774760, 19519767.
15. Schneiker S, Perlova O, Kaiser O, Gerth K, Alici A, Altmeyer MO, Bartels D, Bekel T, Beyer S, Bode E, et al. Complete genome sequence of the myxobacterium Sorangium cellulosum. Nat Biotechnol 2007, 25(11):1281-1289. 10.1038/nbt1354, 17965706.
16. Bon RS, Waldmann H. Bioactivity-guided navigation of chemical space. Acc Chem Res 2010, 43(8):1103-1114. 10.1021/ar100014h, 20481515.
17. Weissman KJ, Muller R. A brief tour of myxobacterial secondary metabolism. Bioorg Med Chem 2009, 17(6):2121-2136. 10.1016/j.bmc.2008.11.025, 19109025.
18. Silakowski B, Kunze B, Muller R. Multiple hybrid polyketide synthase/non-ribosomal peptide synthetase gene clusters in the myxobacterium Stigmatella aurantiaca. Gene 2001, 275(2):233-240. 10.1016/S0378-1119(01)00680-1, 11587850.
19. Rix U, Fischer C, Remsing LL, Rohr J. Modification of post-PKS tailoring steps through combinatorial biosynthesis. Nat Prod Rep 2002, 19(5):542-580. 10.1039/b103920m, 12430723.
20. Davies J, Spiegelman GB, Yim G. The world of subinhibitory antibiotic concentrations. Curr Opin Microbiol 2006, 9(5):445-453. 10.1016/j.mib.2006.08.006, 16942902.
21. Bode HB, Muller R. The impact of bacterial genomics on natural product research. Angew Chem Int Ed 2005, 44(42):6828-6846.
22. Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, et al. Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature 2002, 417(6885):141-147. 10.1038/417141a, 12000953.
23. Ikeda H, Ishikawa J, Hanamoto A, Shinose M, Kikuchi H, Shiba T, Sakaki Y, Hattori M, Omura S. Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis. Nat Biotechnol 2003, 21(5):526-531. 10.1038/nbt820, 12692562.
24. Hong J. Role of natural product diversity in chemical biology. Curr Opin Chem Biol 2011, 15(3):350-354. 10.1016/j.cbpa.2011.03.004, 3110584, 21489856.
25. Scheller N, Mina LB, Galao RP, Chari A, Gimenez-Barcons M, Noueiry A, Fischer U, Meyerhans A, Diez J. Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates. Proc Natl Acad Sci USA 2009, 106(32):13517-13522. 10.1073/pnas.0906413106, 2714764, 19628699.
26. Schneider K, Kromer JO, Wittmann C, Alves-Rodrigues I, Meyerhans A, Diez J, Heinzle E. Metabolite profiling studies in Saccharomyces cerevisiae: an assisting tool to prioritize host targets for antiviral drug screening. Microb Cell Fact 2009, 8:12. 10.1186/1475-2859-8-12, 2658664, 19183481.
27. Diez J, Ishikawa M, Kaido M, Ahlquist P. Identification and characterization of a host protein required for efficient template selection in viral RNA replication. Proc Natl Acad Sci USA 2000, 97(8):3913-3918. 10.1073/pnas.080072997, 18116, 10759565.
28. Mas A, Alves-Rodrigues I, Noueiry A, Ahlquist P, Diez J. Host deadenylation-dependent mRNA decapping factors are required for a key step in brome mosaic virus RNA replication. J Virol 2006, 80(1):246-251. 10.1128/JVI.80.1.246-251.2006, 1317526, 16352549.
29. Noueiry AO, Diez J, Falk SP, Chen J, Ahlquist P. Yeast Lsm1p-7p/Pat1p deadenylation-dependent mRNA-decapping factors are required for brome mosaic virus genomic RNA translation. Mol Cell Biol 2003, 23(12):4094-4106. 10.1128/MCB.23.12.4094-4106.2003, 156131, 12773554.
30. de Fernandez MT F, Eoyang L, August JT. Factor fraction required for the synthesis of bacteriophage Qbeta-RNA. Nature 1968, 219(5154):588-590. 10.1038/219588a0, 4874917.
31. Andexer JN, Kendrew SG, Nur-e-Alam M, Lazos O, Foster TA, Zimmermann AS, Warneck TD, Suthar D, Coates NJ, Koehn FE, et al. Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismate. Proc Natl Acad Sci USA 2011, 108(12):4776-4781. 10.1073/pnas.1015773108, 3064383, 21383123.
32. Mestres J, Seifert SA, Oprea TI. Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome. Clin Pharmacol Ther 2011, 90(5):662-665. 10.1038/clpt.2011.177, 21975349.
33. Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 2010, 62(45):491-502.
34. Villaverde A. Nanotechnology, bionanotechnology and microbial cell factories. Microb Cell Fact 2010, 9:53. 10.1186/1475-2859-9-53, 2916890, 20602780.
35. Zhang MQ, Gaisser S, Nur EAM, Sheehan LS, Vousden WA, Gaitatzis N, Peck G, Coates NJ, Moss SJ, Radzom M, et al. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors. J Med Chem 2008, 51(18):5494-5497. 10.1021/jm8006068, 18800759.